Document Detail


Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
MedLine Citation:
PMID:  17384438     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: Heart failure causes more than 1 million US hospitalizations yearly, mostly related to congestion. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promise in this condition.
OBJECTIVE: To evaluate short-term effects of tolvaptan when added to standard therapy in patients hospitalized with heart failure.
DESIGN, SETTING, AND PATIENTS: Two identical prospective, randomized, double-blind, placebo-controlled trials at 359 sites in North America, South America, and Europe were conducted during the inpatient period of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) between October 7, 2003, and February 3, 2006. A total of 2048 (trial A) and 2085 (trial B) patients hospitalized with heart failure and congestion were studied.
INTERVENTION: Patients were randomized to receive either tolvaptan (30 mg/d) or matching placebo, within 48 hours of admission.
MAIN OUTCOME MEASURES: Primary end point was a composite of changes in global clinical status based on a visual analog scale and body weight at day 7 or discharge if earlier. Secondary end points included dyspnea (day 1), global clinical status (day 7 or discharge), body weight (days 1 and 7 or discharge), and peripheral edema (day 7 or discharge).
RESULTS: Rank sum analysis of the composite primary end point showed greater improvement with tolvaptan vs placebo (trial A, mean [SD], 1.06 [0.43] vs 0.99 [0.44]; and trial B, 1.07 [0.42] vs 0.97 [0.43]; both trials P<.001). Mean (SD) body weight reduction was greater with tolvaptan on day 1 (trial A, 1.71 [1.80] vs 0.99 [1.83] kg; P<.001; and trial B, 1.82 [2.01] vs 0.95 [1.85] kg; P<.001) and day 7 or discharge (trial A, 3.35 [3.27] vs 2.73 [3.34] kg; P<.001; and trial B, 3.77 [3.59] vs 2.79 [3.46] kg; P<.001), whereas improvements in global clinical status were not different between groups. More patients receiving tolvaptan (684 [76.7%] and 678 [72.1%] for trial A and trial B, respectively) vs patients receiving placebo (646 [70.6%] and 597 [65.3%], respectively) reported improvement in dyspnea at day 1 (both trials P<.001). Edema at day 7 or discharge improved significantly with tolvaptan in trial B (P = .02) but did not reach significance in trial A (P = .07). Serious adverse event frequencies were similar between groups, without excess renal failure or hypotension.
CONCLUSION: In patients hospitalized with heart failure, oral tolvaptan in addition to standard therapy including diuretics improved many, though not all, heart failure signs and symptoms, without serious adverse events.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00071331
Authors:
Mihai Gheorghiade; Marvin A Konstam; John C Burnett; Liliana Grinfeld; Aldo P Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Thomas Cook; John Ouyang; Christopher Zimmer; Cesare Orlandi;
Related Documents :
10796808 - Surgical treatments for ingrowing toenails.
22271898 - Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia ...
12804408 - Antibiotics versus placebo for prevention of postoperative infection after appendicectomy.
19861008 - Assessment of global capacity to conduct tuberculosis drug development trials: do we ha...
20028448 - Photodynamic therapy with 5-aminolevulinic acid in actinic cheilitis: an 18-month clini...
9438318 - Highly effective second-line anti-helicobacter pylori therapy in patients with previous...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2007-03-25
Journal Detail:
Title:  JAMA     Volume:  297     ISSN:  1538-3598     ISO Abbreviation:  JAMA     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-03-29     Completed Date:  2007-03-30     Revised Date:  2014-09-17    
Medline Journal Info:
Nlm Unique ID:  7501160     Medline TA:  JAMA     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1332-43     Citation Subset:  AIM; IM    
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00071331
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Aged
Aged, 80 and over
Benzazepines / therapeutic use*
Cardiovascular Agents / therapeutic use*
Diuretics / therapeutic use
Double-Blind Method
Drug Therapy, Combination
Female
Furosemide / therapeutic use
Heart Failure / drug therapy*
Hospitalization
Humans
Male
Middle Aged
Receptors, Vasopressin / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Benzazepines; 0/Cardiovascular Agents; 0/Diuretics; 0/Receptors, Vasopressin; 150683-30-0/tolvaptan; 7LXU5N7ZO5/Furosemide
Comments/Corrections
Comment In:
Curr Heart Fail Rep. 2009 Mar;6(1):3-4   [PMID:  19278050 ]
JAMA. 2007 Mar 28;297(12):1374-6   [PMID:  17384439 ]
Curr Cardiol Rep. 2008 May;10(3):166-7   [PMID:  18489858 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome ...
Next Document:  Prolonged treatment of primary hepatocytes with oleate induces insulin resistance through p38 mitoge...